TAA05 Cell Injection in the Treatment of Recurrent / Refractory Acute Myeloid Leukemia

NARecruitingINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

July 1, 2021

Primary Completion Date

October 31, 2023

Study Completion Date

October 31, 2025

Conditions
CARAcute Myeloid Leukemia
Interventions
DRUG

TAA05 cell injection

"Chimeric antigen receptor T cells (car-t)~Chimeric antigen receptor T cells (car-t) is one of the most effective therapies for malignant tumors (especially hematological tumors). Like other immunotherapies, the basic principle is to use the patient's own immune cells to clear cancer cells. Chimeric antigen receptor (car) is the core component of car-t, which endows T cells with the ability to recognize tumor antigens in an independent manner,which enables car modified T cells to recognize a wider range of targets than natural T cell surface receptors (TCR). The basic design of car includes a tumor associated antigen binding region (usually derived from scFv segment of monoclonal antibody antigen binding region), transmembrane region and intracellular signal region. The selection of target antigen is a key determinant for the specificity and effectiveness of car and the safety of genetically modified T cells."

Trial Locations (1)

230000

RECRUITING

Anhui Provincial Hospital, Hefei

All Listed Sponsors
collaborator

Anhui Provincial Hospital

OTHER_GOV

lead

PersonGen BioTherapeutics (Suzhou) Co., Ltd.

INDUSTRY